Science Applications International Corporation (SAIC) (NYSE: SAI) announced today it was awarded a contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to provide preclinical services for the development of biopharmaceutical products for infectious diseases. The contract was funded $1.9 million at the end of fiscal year 2011. The total funding could be up to $102 million over the ten year period of performance, subject to availability of annual appropriations.
Research supported by NIAID, NIH, and the Department of Health and Human Services strives to understand, treat and ultimately prevent a myriad of infectious, immunologic and allergic diseases that threaten millions of human lives. Under the contract, SAIC will provide a suite of biopharmaceutical product development services, either directly or through management of subcontractors in areas including: feasibility assessments, assay development, process development, cGMP manufacture, and regulatory activities.
"SAIC is pleased to assist and support NIAID with the development of biopharmaceutical products that will help prevent harmful diseases and improve human health," said Steve Comber, SAIC senior vice president and business unit general manager.
Annual COVID-19 vaccine proves to be a wise investment for personal health and pocketbook